FindTrial
Sign In

Vimentin: A Key Protein Studied in Young Women with Triple Negative Breast Cancer to Understand How Aggressive the Disease Is

Immunochistochemical evaluation of Vimentin in triple negative breast carcinoma in young females with its relation to other clinicopathological parameters - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/103365
Enrollment
60
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C509- Malignant neoplasm of breast of unspecified site

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

MUSKAAN BHATNAGAR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Resected specimens of Invasive ductal carcinoma confirmed on histopathology. Molecular subtype of TNBC confirmed on IHC.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Correlation of vimentin expression with clinicopathological parameters including tumor size, grade, lymphovascular invasion, lymph node status, and stage.Timepoint: At baseline.—

Primary

MeasureTime frame
To determine the frequency of vimentin positivity and its expression levels in TNBC cases in females under 50 years using immunohistochemistry.Timepoint: At baseline four weeks to 8 weeks—

Countries

India

Contacts

Public ContactMUSKAAN BHATNAGAR

JNMC WARDHA

prg835@gmail.com9373101668

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026